metformin has been researched along with Diabetic Cardiomyopathies in 39 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a population-based case-control study to assess the myocardial infarction (MI) and stroke risks associated with sulphonylureas and insulin when used in combination with metformin." | 7.81 | Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. ( Dublin, S; Flory, JH; Floyd, JS; Heckbert, SR; Psaty, BM; Sitlani, CM; Smith, NL; Wiggins, KL, 2015) |
| "The safety of metformin in heart failure has been questioned because of a perceived risk of life-threatening lactic acidosis, though recent studies have not supported this concern." | 7.76 | Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. ( Abildstrøm, SZ; Andersson, C; Gislason, GH; Hansen, PR; Jørgensen, CH; Køber, L; Lange, T; Norgaard, ML; Olesen, JB; Schramm, TK; Torp-Pedersen, C; Vaag, A; Weeke, P, 2010) |
| "Hydrogen is a novel medical gas with several properties, including anti-oxidative, anti-inflammatory, anti-apoptotic, anti-allergic, and energy metabolism stimulating properties." | 5.72 | Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy. ( Bai, J; Hong, X; Liu, J; Nie, C; Pan, S; Wang, B; Xi, S; Yang, W; Yu, M; Zou, R, 2022) |
| "To investigate the therapeutic effect of methyl-3β-hydroxylanosta-9,24-dien-21-oate (RA3), in the absence or presence of the anti-diabetic drug, metformin (MET), against hyperglycemia-induced cardiac injury using an in vitro H9c2 cell model." | 4.02 | The triterpene, methyl-3β-hydroxylanosta-9,24-dien-21-oate (RA3), attenuates high glucose-induced oxidative damage and apoptosis by improving energy metabolism. ( Dludla, PV; Johnson, R; Kappo, AP; Mosa, RA; Muller, CJF; Opoku, AR; Sangweni, NF, 2021) |
| "In intention-to-treat analyses, there was no difference in the risk of any cardiovascular event among the add-on combination treatment groups, but significantly lower risks of acute myocardial infarction were found for the glinides plus metformin treatment group (crude hazard ratio 0." | 3.81 | Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. ( Chang, CH; Chang, YC; Chen, ST; Chuang, LM; Lai, MS; Lin, JW, 2015) |
| "We conducted a population-based case-control study to assess the myocardial infarction (MI) and stroke risks associated with sulphonylureas and insulin when used in combination with metformin." | 3.81 | Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. ( Dublin, S; Flory, JH; Floyd, JS; Heckbert, SR; Psaty, BM; Sitlani, CM; Smith, NL; Wiggins, KL, 2015) |
| "The safety of metformin in heart failure has been questioned because of a perceived risk of life-threatening lactic acidosis, though recent studies have not supported this concern." | 3.76 | Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. ( Abildstrøm, SZ; Andersson, C; Gislason, GH; Hansen, PR; Jørgensen, CH; Køber, L; Lange, T; Norgaard, ML; Olesen, JB; Schramm, TK; Torp-Pedersen, C; Vaag, A; Weeke, P, 2010) |
| " The most common adverse events with exenatide QWS-AI were gastrointestinal events and injection-site reactions." | 2.84 | Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. ( Gadde, KM; Hardy, E; Iqbal, N; Öhman, P; Vetter, ML, 2017) |
| "Metformin has displayed definite CV benefits related to AMPK." | 2.61 | AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. ( Li, J; Li, X; Liu, J; Lu, Q; Ren, D; Rousselle, T; Sun, X; Tong, N, 2019) |
| "In patients with type 2 diabetes mellitus, treatment with metformin is associated with a lower cardiovascular morbidity and mortality, compared with alternative glucose-lowering drugs." | 2.47 | The cardioprotective effects of metformin. ( de Boer, RA; El Messaoudi, S; Riksen, NP; Rongen, GA, 2011) |
| "Metformin was used as the antidiabetic drug." | 1.91 | Ferulic acid mitigates diabetic cardiomyopathy via modulation of metabolic abnormalities in cardiac tissues of diabetic rats. ( Erukainure, OL; Ijomone, OK; Islam, MS; Msomi, NZ; Olofinsan, KA; Salau, VF, 2023) |
| "Metformin treatment markedly attenuated cardiac fibrosis in db/db mice and the proliferation and migration of CFs under high-glucose conditions." | 1.91 | Metformin suppresses cardiac fibroblast proliferation under high-glucose conditions via regulating the mitochondrial complex I protein Grim-19 involved in the Sirt1/Stat3 signaling pathway. ( Cui, X; Han, B; Li, Y; Liu, X; Ma, S; Pan, H; Wan, L; Wei, J, 2023) |
| "Hydrogen is a novel medical gas with several properties, including anti-oxidative, anti-inflammatory, anti-apoptotic, anti-allergic, and energy metabolism stimulating properties." | 1.72 | Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy. ( Bai, J; Hong, X; Liu, J; Nie, C; Pan, S; Wang, B; Xi, S; Yang, W; Yu, M; Zou, R, 2022) |
| "Metformin was used as the positive control." | 1.72 | Cinnamic acid is beneficial to diabetic cardiomyopathy via its cardioprotective, anti-inflammatory, anti-dyslipidemia, and antidiabetic properties. ( Nair, A; Preetha Rani, MR; Raghu, KG; Rajankutty, K; Ranjit, S; Salin Raj, P, 2022) |
| "Metformin was administered intragastrically, and aerobic exercise was performed using treadmill with 7-12 m/min, 30-40 min/day, 5 days/week." | 1.62 | Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments. ( Liu, J; Lu, J; Tang, Q; Wang, X; Zhang, L; Zhang, Y, 2021) |
| "Metformin is an AMP kinase (AMPK) activator, the widest used antidiabetic drug." | 1.62 | Metformin impairs homing ability and efficacy of mesenchymal stem cells for cardiac repair in streptozotocin-induced diabetic cardiomyopathy in rats. ( Ammar, HI; Ashour, H; Dhingra, S; Fadel, M; Kamar, SS; Rashed, LA; Shamseldeen, AM; Shoukry, HS; Srivastava, A, 2021) |
| "Metformin use was associated with reduced lipid accumulation independently of immunosuppressive therapy." | 1.56 | Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. ( Amarelli, C; Balestrieri, ML; Cacciatore, F; D'Amico, M; D'Onofrio, N; De Feo, M; Esposito, S; Golino, P; Maiello, C; Mansueto, G; Marfella, R; Mattucci, I; Napoli, C; Paolisso, G; Salerno, G, 2020) |
| "Metformin is a widely used antidiabetic drug for type 2 diabetes that can play a cardioprotective role through multiple pathways." | 1.51 | Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. ( Bai, Y; Che, H; Li, Y; Lv, J; Meng, S; Qin, Y; Wang, L; Wang, Y; Xian, H; Yang, F; Yu, Y, 2019) |
| "469 ambulatory type 2 diabetes patients (mean diabetes duration 10." | 1.46 | Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. ( Fleischer, J; Hansen, CS; Jensen, JS; Jørgensen, ME; Ridderstråle, M; Vistisen, D, 2017) |
| "Myocardial fibrosis is a key process in diabetic cardiomyopathy." | 1.39 | Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. ( Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (56.41) | 24.3611 |
| 2020's | 17 (43.59) | 2.80 |
| Authors | Studies |
|---|---|
| Luan, Y | 2 |
| Feng, Q | 1 |
| Chen, X | 1 |
| Ren, KD | 1 |
| Yang, Y | 1 |
| Lu, J | 4 |
| Liu, J | 5 |
| Zhang, L | 3 |
| Wang, X | 1 |
| Zhang, Y | 3 |
| Tang, Q | 3 |
| Zou, R | 1 |
| Nie, C | 1 |
| Pan, S | 1 |
| Wang, B | 1 |
| Hong, X | 1 |
| Xi, S | 1 |
| Bai, J | 1 |
| Yu, M | 1 |
| Yang, W | 1 |
| Dia, M | 1 |
| Leon, C | 1 |
| Chanon, S | 1 |
| Bendridi, N | 1 |
| Gomez, L | 1 |
| Rieusset, J | 1 |
| Thibault, H | 1 |
| Paillard, M | 1 |
| Salau, VF | 1 |
| Erukainure, OL | 1 |
| Olofinsan, KA | 1 |
| Msomi, NZ | 1 |
| Ijomone, OK | 1 |
| Islam, MS | 1 |
| Nair, A | 1 |
| Preetha Rani, MR | 1 |
| Salin Raj, P | 1 |
| Ranjit, S | 1 |
| Rajankutty, K | 1 |
| Raghu, KG | 1 |
| Sun, S | 1 |
| Dawuti, A | 1 |
| Gong, D | 1 |
| Wang, R | 1 |
| Yuan, T | 1 |
| Wang, S | 1 |
| Xing, C | 1 |
| Lu, Y | 1 |
| Du, G | 1 |
| Fang, L | 1 |
| Liu, Y | 2 |
| Gao, Y | 2 |
| Yuan, X | 2 |
| Xiang, M | 2 |
| Li, Y | 2 |
| Liu, X | 1 |
| Wan, L | 1 |
| Han, B | 1 |
| Ma, S | 1 |
| Pan, H | 1 |
| Wei, J | 1 |
| Cui, X | 1 |
| Yan, X | 1 |
| Xu, P | 1 |
| Zhou, L | 1 |
| Tang, H | 1 |
| Zheng, Y | 1 |
| Cao, H | 1 |
| Marfella, R | 1 |
| Amarelli, C | 1 |
| Cacciatore, F | 1 |
| Balestrieri, ML | 1 |
| Mansueto, G | 1 |
| D'Onofrio, N | 1 |
| Esposito, S | 1 |
| Mattucci, I | 1 |
| Salerno, G | 1 |
| De Feo, M | 1 |
| D'Amico, M | 1 |
| Golino, P | 1 |
| Maiello, C | 1 |
| Paolisso, G | 1 |
| Napoli, C | 1 |
| Packer, M | 1 |
| IJzerman, RG | 1 |
| Vrijlandt, PJWS | 1 |
| Ammar, HI | 1 |
| Shamseldeen, AM | 1 |
| Shoukry, HS | 1 |
| Ashour, H | 1 |
| Kamar, SS | 1 |
| Rashed, LA | 1 |
| Fadel, M | 1 |
| Srivastava, A | 1 |
| Dhingra, S | 1 |
| Sangweni, NF | 1 |
| Mosa, RA | 1 |
| Dludla, PV | 1 |
| Kappo, AP | 1 |
| Opoku, AR | 1 |
| Muller, CJF | 1 |
| Johnson, R | 1 |
| Castan-Laurell, I | 1 |
| Dray, C | 1 |
| Valet, P | 1 |
| Eraky, SM | 1 |
| Ramadan, NM | 1 |
| Raz, I | 1 |
| Mosenzon, O | 1 |
| Bonaca, MP | 1 |
| Cahn, A | 1 |
| Kato, ET | 1 |
| Silverman, MG | 1 |
| Bhatt, DL | 1 |
| Leiter, LA | 1 |
| McGuire, DK | 1 |
| Wilding, JPH | 1 |
| Gause-Nilsson, IAM | 1 |
| Langkilde, AM | 1 |
| Johansson, PA | 1 |
| Sabatine, MS | 1 |
| Wiviott, SD | 1 |
| Al-Assi, O | 1 |
| Ghali, R | 1 |
| Mroueh, A | 1 |
| Kaplan, A | 1 |
| Mougharbil, N | 1 |
| Eid, AH | 1 |
| Zouein, FA | 1 |
| El-Yazbi, AF | 1 |
| Hopf, AE | 1 |
| Andresen, C | 1 |
| Kötter, S | 1 |
| Isić, M | 1 |
| Ulrich, K | 1 |
| Sahin, S | 1 |
| Bongardt, S | 1 |
| Röll, W | 1 |
| Drove, F | 1 |
| Scheerer, N | 1 |
| Vandekerckhove, L | 1 |
| De Keulenaer, GW | 1 |
| Hamdani, N | 1 |
| Linke, WA | 1 |
| Krüger, M | 1 |
| Al-Damry, NT | 1 |
| Attia, HA | 1 |
| Al-Rasheed, NM | 2 |
| Mohamad, RA | 1 |
| Al-Amin, MA | 1 |
| Dizmiri, N | 1 |
| Atteya, M | 1 |
| Liu, C | 1 |
| Hua, N | 1 |
| Fu, X | 1 |
| Pan, Y | 1 |
| Li, B | 1 |
| Li, X | 2 |
| Abdel-Hamid, AAM | 1 |
| Firgany, AEL | 1 |
| Mormile, R | 1 |
| Lu, Q | 1 |
| Sun, X | 1 |
| Rousselle, T | 1 |
| Ren, D | 1 |
| Tong, N | 1 |
| Li, J | 1 |
| Yang, F | 1 |
| Qin, Y | 1 |
| Wang, Y | 1 |
| Meng, S | 1 |
| Xian, H | 1 |
| Che, H | 1 |
| Lv, J | 1 |
| Yu, Y | 1 |
| Bai, Y | 1 |
| Wang, L | 1 |
| Chen, WJ | 1 |
| Greulich, S | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| Lamb, HJ | 1 |
| de Roos, A | 1 |
| Smit, JW | 1 |
| Romijn, JA | 1 |
| Ruige, JB | 1 |
| Lammertsma, AA | 1 |
| Lubberink, M | 1 |
| Diamant, M | 1 |
| Ouwens, DM | 1 |
| Picatoste, B | 1 |
| Ramírez, E | 1 |
| Caro-Vadillo, A | 1 |
| Iborra, C | 1 |
| Ares-Carrasco, S | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, O | 1 |
| Levitt Katz, L | 1 |
| Gidding, SS | 1 |
| Bacha, F | 1 |
| Hirst, K | 1 |
| McKay, S | 1 |
| Pyle, L | 1 |
| Lima, JA | 1 |
| Breunig, IM | 1 |
| Shaya, FT | 1 |
| McPherson, ML | 1 |
| Snitker, S | 1 |
| Jiménez-Amilburu, V | 1 |
| Jong-Raadsen, S | 1 |
| Bakkers, J | 1 |
| Spaink, HP | 1 |
| Marín-Juez, R | 1 |
| Chang, YC | 1 |
| Chuang, LM | 1 |
| Lin, JW | 1 |
| Chen, ST | 1 |
| Lai, MS | 1 |
| Chang, CH | 1 |
| Floyd, JS | 1 |
| Wiggins, KL | 1 |
| Sitlani, CM | 1 |
| Flory, JH | 1 |
| Dublin, S | 1 |
| Smith, NL | 1 |
| Heckbert, SR | 1 |
| Psaty, BM | 1 |
| Hansen, CS | 1 |
| Jensen, JS | 1 |
| Ridderstråle, M | 1 |
| Vistisen, D | 1 |
| Jørgensen, ME | 1 |
| Fleischer, J | 1 |
| Gadde, KM | 1 |
| Vetter, ML | 1 |
| Iqbal, N | 1 |
| Hardy, E | 1 |
| Öhman, P | 1 |
| Andersson, C | 1 |
| Olesen, JB | 1 |
| Hansen, PR | 1 |
| Weeke, P | 1 |
| Norgaard, ML | 1 |
| Jørgensen, CH | 1 |
| Lange, T | 1 |
| Abildstrøm, SZ | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, GH | 1 |
| El Messaoudi, S | 1 |
| Rongen, GA | 1 |
| de Boer, RA | 1 |
| Riksen, NP | 1 |
| Da Silva, D | 1 |
| Ausina, P | 1 |
| Alencar, EM | 1 |
| Coelho, WS | 1 |
| Zancan, P | 1 |
| Sola-Penna, M | 1 |
| Dei Cas, A | 1 |
| Spigoni, V | 1 |
| Ridolfi, V | 1 |
| Metra, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lipid Accumulation in Heart Transplant From Non-diabetic Donors to Diabetic Recipients[NCT03546062] | 177 participants (Actual) | Observational | 2010-01-01 | Completed | |||
| Investigation of Association Between Single Nucleotide Polymorphisms in Genes of the Apelin/ APJ System (-1860T>C & G212A) and CAD Risk and Hypertension in Syrian Patients[NCT05562687] | 230 participants (Actual) | Observational | 2019-12-15 | Completed | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus[NCT01652729] | Phase 3 | 365 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Authors will evaluate myocyte lipid accumulation as Oil Red-O positive biopsie after heart transplant at follow up. (NCT03546062)
Timeframe: 12 months.
| Intervention | Endomyocardial Biopsies (Count of Units) |
|---|---|
| Diabetic Metformin Group | 54 |
| Diabetic Group Without Metformin Therapy | 21 |
| Non-diabetic Group | 0 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
The change in 2-hour postprandial plasma glucose from baseline (Day 1) to Visit 8 (Week 16) was analyzed using a general linear model including treatment, and baseline HbA1c stratum (< 9% or ≥ 9%) as fixed factors, and the baseline 2-hour postprandial plasma glucose concentrations as a covariate. (NCT01652729)
Timeframe: Baseline to Week 16
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -59.57 |
| Active Comparator: Sitagliptin | -23.61 |
| Placebo Comparator: Placebo | -38.68 |
The change in body weight (kg) from baseline (Day 1) to Week 28/Study Termination. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | kg (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -1.12 |
| Active Comparator: Sitagliptin | -1.19 |
| Placebo Comparator: Placebo | 0.15 |
The change in fasting plasma glucose concentrations from baseline (Day 1) to Week 28/Study Termination. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -21.3 |
| Active Comparator: Sitagliptin | -11.3 |
| Placebo Comparator: Placebo | 9.6 |
Absolute change in HbA1c from baseline (Day 1, Visit 3) to Week 28/Study Termination (Visit 11). Hypothesis testing on the primary endpoint followed a serial gated procedure with all tests carried out at a 2-sided significance level of 0.05 to protect the family-wise error rate. These tests were conducted sequentially, and are presented in the statistical analysis section below in the order in which they were performed; each test was the gatekeeper of later tests. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | percentage of total hemoglobin (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -1.13 |
| Active Comparator: Sitagliptin | -0.75 |
| Placebo Comparator: Placebo | -0.40 |
Percentage of subjects achieving HbA1c target values of < 7.0% at Week 28/Study Termination. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | percentage of subjects (Number) | |||
|---|---|---|---|---|
| Baseline Yes | Baseline No | Week 28 Yes | Week 28 No | |
| Active Comparator: Sitagliptin | 1.6 | 98.4 | 32.0 | 68.0 |
| Experimental: Exenatide | 3.3 | 96.7 | 43.1 | 56.9 |
| Placebo Comparator: Placebo | 3.3 | 96.7 | 24.6 | 75.4 |
7 reviews available for metformin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Emerging Role of Mitophagy in the Heart: Therapeutic Potentials to Modulate Mitophagy in Cardiac Diseases.
Topics: Diabetic Cardiomyopathies; Heart Diseases; Humans; Metformin; MicroRNAs; Microtubule-Associated Prot | 2021 |
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Biomarkers; Blood Glucose; Diabetes Mellitus; Dia | 2020 |
[New and old glucose lowering drugs; a state-of-the-art review].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibit | 2020 |
The therapeutic potentials of apelin in obesity-associated diseases.
Topics: Animals; Anti-Obesity Agents; Apelin; Apelin Receptors; Diabetes Mellitus, Type 2; Diabetic Cardiomy | 2021 |
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases.
Topics: AMP-Activated Protein Kinases; Animals; Coronary Artery Disease; Diabetes Mellitus; Diabetic Cardiom | 2019 |
The cardioprotective effects of metformin.
Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Cardiomyo | 2011 |
Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach.
Topics: Chronic Disease; Diabetes Mellitus; Diabetic Cardiomyopathies; Heart Failure; Humans; Hypoglycemic A | 2013 |
4 trials available for metformin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as | 2018 |
Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.
Topics: Activins; Adipose Tissue; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyop | 2013 |
Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial.
Topics: Adolescent; Atrial Function, Left; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Diabet | 2015 |
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 2017 |
28 other studies available for metformin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments.
Topics: Animals; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Hydrogen; Metformin; | 2022 |
Effect of Metformin on T2D-Induced MAM Ca
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Heart Failure | 2022 |
Ferulic acid mitigates diabetic cardiomyopathy via modulation of metabolic abnormalities in cardiac tissues of diabetic rats.
Topics: Acetylcholinesterase; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabete | 2023 |
Cinnamic acid is beneficial to diabetic cardiomyopathy via its cardioprotective, anti-inflammatory, anti-dyslipidemia, and antidiabetic properties.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Hypog | 2022 |
Puerarin-V Improve Mitochondrial Respiration and Cardiac Function in a Rat Model of Diabetic Cardiomyopathy via Inhibiting Pyroptosis Pathway through P2X7 Receptors.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Metformin; Myocardium; Pyroptos | 2022 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.
Topics: Animals; Diabetic Cardiomyopathies; Fibrosis; Interleukin-6; Metformin; Mice; NF-kappa B; Transformi | 2023 |
Metformin suppresses cardiac fibroblast proliferation under high-glucose conditions via regulating the mitochondrial complex I protein Grim-19 involved in the Sirt1/Stat3 signaling pathway.
Topics: Animals; Cell Proliferation; Diabetic Cardiomyopathies; Electron Transport Complex I; Fibroblasts; F | 2023 |
Blockade of high mobility group box 1 involved in the protective of curcumin on myocardial injury in diabetes in vivo and in vitro.
Topics: Animals; Cardiotonic Agents; Caspase 1; Cell Line; Cell Survival; Curcumin; Diabetes Mellitus, Exper | 2020 |
Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients.
Topics: Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Follow-Up Studies; Heart Failure; Hear | 2020 |
Metformin impairs homing ability and efficacy of mesenchymal stem cells for cardiac repair in streptozotocin-induced diabetic cardiomyopathy in rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cell Movement; Cell Survival; Cells, Cultured | 2021 |
The triterpene, methyl-3β-hydroxylanosta-9,24-dien-21-oate (RA3), attenuates high glucose-induced oxidative damage and apoptosis by improving energy metabolism.
Topics: Animals; Antioxidants; Apoptosis; Caspases; Cell Line; Diabetic Cardiomyopathies; Energy Metabolism; | 2021 |
Effects of omega-3 fatty acids and metformin combination on diabetic cardiomyopathy in rats through autophagic pathway.
Topics: Animals; Autophagy; Calcineurin; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fa | 2021 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Into | 2018 |
Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1.
Topics: Animals; Cells, Cultured; Connectin; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Diabetic Card | 2018 |
Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Apoptosis; Biomarkers; | 2018 |
Metformin Regulates the Expression of SK2 and SK3 in the Atria of Rats With Type 2 Diabetes Mellitus Through the NOX4/p38MAPK Signaling Pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Gene | 2018 |
Favorable outcomes of metformin on coronary microvasculature in experimental diabetic cardiomyopathy.
Topics: Animals; Coronary Vessels; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Hypoglycemic | 2018 |
Cardioprotection by metformin in type 2 diabetes: what is the truth?
Topics: Cardiotonic Agents; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Hepatocyte Growth Factor; | 2019 |
Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Blotting, Western; Cells, Cultured; Diabetic Card | 2019 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Di | 2013 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Fema | 2014 |
GLUT12 deficiency during early development results in heart failure and a diabetic phenotype in zebrafish.
Topics: Animals; Animals, Genetically Modified; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diseas | 2015 |
Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Topics: Administration, Oral; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic A | 2015 |
Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopath | 2015 |
Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Cohort Studies; | 2017 |
Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
Topics: Aged; Aged, 80 and over; Cause of Death; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabeti | 2010 |
Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathi | 2012 |